Contineum Therapeutics 2026 shareholder meeting results

Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026.

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. As of the record date of April 27, 2026, there were 32,723,877 shares of Class A common stock outstanding and entitled to vote.

Stockholders elected three Class II directors to serve until the 2029 annual meeting. Evert Schimmelpennink received 21,773,559 votes for and 131,384 withheld; Lori M. Lyons-Williams received 20,593,715 for and 1,311,228 withheld; and Diego Miralles, M.D. received 21,673,187 for and 231,756 withheld. Each proposal had 6,133,812 broker non-votes.

Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,021,047 votes for, 16,104 against and 1,604 withheld.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares entitled to vote: 32,723,877 shares Votes for Evert Schimmelpennink: 21,773,559 votes Votes for Lori M. Lyons-Williams: 20,593,715 votes +4 more

7 metrics

Shares entitled to vote 32,723,877 shares Class A common stock as of April 27, 2026 record date

Votes for Evert Schimmelpennink 21,773,559 votes Election as Class II director at 2026 annual meeting

Votes for Lori M. Lyons-Williams 20,593,715 votes Election as Class II director at 2026 annual meeting

Votes for Diego Miralles, M.D. 21,673,187 votes Election as Class II director at 2026 annual meeting

Broker non-votes on director items 6,133,812 votes Per director proposal at 2026 annual meeting

Votes for auditor ratification 28,021,047 votes Ratification of Ernst & Young LLP for fiscal year 2026

Votes against auditor ratification 16,104 votes Ratification of Ernst & Young LLP for fiscal year 2026

Key Terms

Annual Meeting of Stockholders, record date, Class II directors, broker non-votes, +1 more

5 terms

Annual Meeting of Stockholders financial

"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."

record date financial

"As of April 27, 2026, the record date for the Annual Meeting"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

Class II directors financial

"elected the three persons listed below as Class II directors"

broker non-votes financial

"The final voting results are as follows ... Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Contineum Therapeutics (CTNM) vote on at the 2026 annual meeting?

Stockholders elected three Class II directors and ratified Ernst & Young LLP as auditor for 2026. These routine governance items confirm the company’s board composition and external financial auditor for the current fiscal year.

How many Contineum Therapeutics (CTNM) shares were eligible to vote at the 2026 annual meeting?

As of the April 27, 2026 record date, 32,723,877 Class A common shares were outstanding and entitled to vote. This figure represents the voting base used to determine approval of directors and the auditor ratification proposal.

Were the director nominees at Contineum Therapeutics’ 2026 meeting elected by stockholders?

Yes. All three Class II director nominees—Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D.—received more votes for than withheld. They will serve until the 2029 annual meeting or until their successors are chosen.

What were the vote results for CTNM director Lori M. Lyons-Williams?

Lori M. Lyons-Williams received 20,593,715 votes for election and 1,311,228 votes withheld, with 6,133,812 broker non-votes. She was elected as a Class II director to serve until the 2029 annual meeting.

Which audit firm did Contineum Therapeutics’ stockholders ratify for fiscal 2026?

Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 28,021,047 votes for, 16,104 against and 1,604 votes withheld.

What are broker non-votes in the Contineum Therapeutics 2026 director election results?

Broker non-votes are shares held by brokers that were not voted on the director proposals, often when instructions are missing. Each director proposal at the 2026 meeting showed 6,133,812 broker non-votes in the final tally.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:48 PM Learn about SEC filing dates

0001855175FALSE00018551752026-03-052026-03-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________________________________________

FORM 8-K

______________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2026

______________________________________________________________________

Contineum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

______________________________________________________________________

Delaware			001-42001			27-1467257
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

3565 General Atomics Court, Suite 200 San Diego, California			92121
(Address of principal executive offices)			(Zip Code)

(858) 333-5280

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

______________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, par value $0.001 per share

CTNM

The Nasdaq Global Market LLC  (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 26, 2026, Contineum Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 27, 2026, the record date for the Annual Meeting, there were 32,723,877 shares of Class A common stock outstanding and entitled to vote at the Annual Meeting. The Annual Meeting was conducted virtually, and the following is a brief summary of the matters voted upon by stockholders at the Annual Meeting.

Proposal 1: Election of Directors

The Company’s stockholders elected the three persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders or until their respective successors have been elected or appointed. The final voting results are as follows:

Director Nominee						Votes For						Votes Withheld						Broker Non-Votes
Evert Schimmelpennink						21,773,559						131,384						6,133,812
Lori M. Lyons-Williams						20,593,715						1,311,228						6,133,812
Diego Miralles, M.D.						21,673,187						231,756						6,133,812

Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

Votes For

Votes Against

Votes Withheld

Broker Non-Votes

28,021,047

16,104

1,604

N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 26, 2026

			Contineum Therapeutics, Inc.
			By:			/s/ Peter Slover
						Peter Slover
						Chief Financial Officer Principal Financial Officer and Principal Accounting Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.9 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 13.3 KB